Evaluating Microarray Pharmacogenetic Testing in Cancer Patients
Trial Parameters
Brief Summary
The purpose of this research is to evaluate the impact of a microarray PGx test on prescribing/dosing of drugs and cancer treatments in patients with cancer who are currently eligible for single-gene DPYD testing.
Eligibility Criteria
Inclusion Criteria: * Written informed consent and HIPAA authorization for release of personal health information. * Age ≥ 18 years at the time of consent. * Eligible for standard of care single-gene DPYD testing (i.e., receiving or expected to receive a fluoropyrimidine-based chemotherapy regimen). The potential participant meets inclusion criteria if the standard of care single-gene DPYD test is planned or previously ordered. If previously ordered, consent must occur no later than 60 days from the date the DPYD results were available. * Willing to provide additional buccal swabs if residual DNA from previous DPYD testing is inadequate for microarray testing. Exclusion Criteria: • History of prior allogeneic hematopoietic cell transplantation or liver transplantation